LENZ THERAPEUTICS, INC. (LENZ) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -126.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-126.00M | (m) |
| 2026-03-31 | (m) | $-109.00M | (m) |
| 2025-12-31 | (m) | $-82.13M | (m) |
| 2025-09-30 | (m) | $-58.88M | (m) |
| 2025-06-30 | (m) | $-52.40M | (m) |
| 2025-03-31 | (m) | $-47.74M | (m) |
| 2024-12-31 | (m) | $-49.77M | (m) |
| 2024-09-30 | (m) | $-115.49M | (m) |
| 2024-06-30 | (m) | $-124.16M | (m) |
| 2024-03-31 | (m) | $-128.63M | (m) |
| 2023-12-31 | (m) | $-124.65M | (m) |
| 2023-09-30 | (m) | $-126.33M | (m) |
| 2023-06-30 | (m) | $-128.53M | (m) |
| 2023-03-31 | (m) | $-99.15M | (m) |
| 2022-12-31 | (m) | $-101.05M | (m) |
| 2022-09-30 | (m) | $-95.38M | (m) |
| 2022-06-30 | (m) | $-85.29M | (m) |
| 2022-03-31 | (m) | $-76.89M | (m) |
| 2021-12-31 | (m) | $-70.76M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-68.37M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |